Nagpur-based pharmaceutical maker specialising in novel drug-delivery technologies — oral thin films, new innovative products and complex generic formulations, plus a nutraceuticals business.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 16 | 16 | 16 | 49 | 49 | 49 | 49 | 54 |
| Reserves | 138 | 145 | 159 | 152 | 190 | 204 | 203 | 243 |
| Borrowings | 90 | 82 | 53 | 62 | 112 | 118 | 121 | 127 |
| Other Liabilities | 82 | 82 | 112 | 79 | 96 | 102 | 94 | 116 |
| Total Liabilities | 325 | 325 | 342 | 342 | 447 | 472 | 467 | 539 |
| AssetsFixed Assets | 116 | 107 | 106 | 109 | 161 | 164 | 187 | 162 |
| CWIP | 10 | 11 | 12 | 27 | 42 | 70 | 46 | 96 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 200 | 208 | 224 | 206 | 244 | 237 | 234 | 282 |
| Total Assets | 325 | 325 | 342 | 342 | 447 | 472 | 467 | 539 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 35 | 22 | 32 | 49 | 38 | 16 | 41 | 50 |
| Cash from Investing | -21 | -19 | -6 | -14 | -35 | -73 | -40 | -55 |
| Cash from Financing | -15 | -2 | -26 | -33 | 1 | 60 | -9 | 28 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 15 | 3 | 25 | 34 | 1 | -57 | 1 | 11 |
| FCF Margin | — | — | — | — | — | — | — | — |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
ZIMLAB · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.